Parabilis Medicines, Inc. (PBLS) Financials

PBLS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 1.2 billion 127.5 million
March 31, 2026 384.2 million 140.0 million
June 30, 2025 ? ?
March 31, 2025 ? ?

PBLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -4.2 million 3.6 million
March 31, 2026 -49.6 million 1.3 million
June 30, 2025 -31.1 million 823000
March 31, 2025 -34.2 million 852000

PBLS Net Income

No data available :(

PBLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 1.1 billion - 41.8 million
March 31, 2026 329.0 million - 43.7 million
June 30, 2025 - - -
March 31, 2025 - - -

PBLS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 28.9 million
March 31, 2026 2.1 million
June 30, 2025 2.0 million
March 31, 2025 2.0 million

PBLS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 616000 39.4 million 11.7 million -
March 31, 2026 369000 37.8 million 9.7 million -
June 30, 2025 16000 30.1 million 5.8 million -
March 31, 2025 74000 33.9 million 6.3 million -

PBLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 148000 -
March 31, 2026 - -
June 30, 2025 - 618000
March 31, 2025 - -

PBLS

Price: $25.89

52 week price:
20.00
42.49

Earnings Per Share: -1.88 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 3.5 billion

Links: